Prenetics Global (PRE) reported a 480% year-over-year revenue increase, fueled by the successful launch of its IM8 diagnostic brand. The surge highlights strong market demand for at-home health testing solutions.
- Prenetics Global (PRE) achieved a 480% year-over-year revenue increase.
- IM8 brand contributed over 60% of total revenue in the latest quarter.
- Revenue reached $147 million, up from $22.5 million in the same quarter last year.
- IM8 integrates genomics and AI for at-home disease detection and health monitoring.
- PRE shares rose 28% in after-hours trading post-earnings release.
- Analysts highlight scalability and global expansion potential of the IM8 platform.
Prenetics Global (PRE) announced a 480% year-over-year increase in revenue, marking one of the most significant growth milestones in the company’s history. The surge was directly attributed to the commercial rollout of its IM8 brand, a new line of at-home diagnostic tests targeting early detection of chronic diseases and personalized health monitoring. The IM8 platform integrates advanced genomics and AI-driven analytics, positioning it as a premium offering in the digital health space. The financial results reflect a shift in consumer behavior toward proactive health management, with IM8 contributing over 60% of the company’s total revenue in the latest quarter. This marks a strategic pivot from Prenetics’ earlier focus on pandemic-related testing, signaling a long-term move into predictive and preventive healthcare. The company reported $147 million in revenue for the quarter, up from $22.5 million during the same period last year. The performance has drawn investor attention, with PRE shares rising 28% in after-hours trading following the announcement. Analysts note that the scalability of the IM8 model—supporting multiple test kits and subscription-based health insights—could drive sustained growth. The success may also influence other health tech firms to accelerate product development in the at-home diagnostics segment. Market indicators such as CL=F (Crude Oil) and ^VIX (CBOE Volatility Index) remained stable during the earnings release, suggesting that the stock movement was company-specific rather than market-wide. The strong fundamentals have prompted several brokerage firms to upgrade their ratings on PRE, citing improved margins and expanding global distribution channels.